A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Molindone (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 20 Nov 2012 Results published in the Media Release.
- 20 Nov 2012 Primary endpoint 'Overt-Aggression-Scale' has not been met.
- 20 Nov 2012 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History